Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival Benefit in Endometrial Carcinoma

AI Analysis of Thymic Health Predicts Immunotherapy Success, Cutting Death Risk by 44%

Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response

Molecular Trojan Horse: Peptide Nanotubes Offer a Path to Defeat Drug-Resistant Tumors

Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers

AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US

LED-Activated SnOx Nanoflake Therapy Destroy Tumor Cells with Precision

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma

Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer

FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer

The VAPOR 2 Trial and the Potential of Water Vapor Ablation in Prostate Cancer Treatment

DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer

Dr. Eleni Lagkadinou Discusses How AbbVie Is Advancing Targeted Innovation for HT Cancers

FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer

Giredestrant Plus Everolimus Improves PF Survival in ER+ Advanced Breast Cancer

Sugary Drinks Drive Colorectal Cancer Metastasis via SORD Pathway, Study Finds

NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer

EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer

Climate-Driven Health Risks to Put $1.5 Trillion in Productivity at Stake by 2050

GSK to invest $30 billion in R&D and Manufacturing in the US over next 5 years

The Role of Third-Generation TKIs in Overcoming Chronic Myeloid Leukemia Resistance

FDA Grants Breakthrough Status to Raludotatug Deruxtecan for Refractory Ovarian Cancer

SUNMO Trial: A New Chapter for Transplant-Ineligible Large B-Cell Lymphoma

The V Foundation and CVC Collaborate to Advance Breast Cancer Vaccine Research

CVC and V Foundation Fuel $500K Grant for Next Phase of Breast Cancer Vaccine Research

The V Foundation for Cancer Research and CVC Partner to Accelerate Breast Cancer Vaccines

ONCOLife’s New Edition Is Live with Breakthroughs in Cancer Research

FDA Grants Breakthrough Status to Izalontamab Brengitecan for EGF+ Lung Cancer

The First FDA-Cleared Blood Test for Alzheimer’s Diagnosis Now Available on the Market